(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 November 2024 (07.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/227930 A1

(51) International Patent Classification:
A61K 47/64 (2017.01) *G01N 33/574* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2024/062286

(22) International Filing Date:
03 May 2024 (03.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23171559.0 04 May 2023 (04.05.2023) EP

(71) Applicant: **AFFIBODY AB** [SE/SE]; Scheeles väg 2, 171 65 Solna (SE).

(72) Inventors: **GUNNERIUSSON, Elin**; Älgövägen 21, 133 36 Saltsjöbaden (SE). **KLINT, Susanne**; Olof Dalins Väg 16, 112 52 Stockholm (SE). **NILSSON, Joakim**; Mörbydalen 5, 8 tr, 182 52 Danderyd (SE).

(74) Agent: **AWA SWEDEN AB**; Box 45086, 104 30 Stockholm (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: NEW POLYPEPTIDE

Figure 15



(57) Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for B7-H3, and provides a B7-H3 binding polypeptide comprising the sequence $EKX_3X_4ALX_7EIX_{10}X_{11}LPNLX_{16}X_{17}X_{18}QX_{20}X_{21}AFIX_{25}X_{26}LNX_{29}X_{30}$ or a sequence having at least 93 % identity thereto. The present disclosure also relates to the use of such a B7-H3 binding polypeptide as a therapeutic, prognostic, diagnostic agent, and/or theranostic agent.

[Continued on next page]

WO 2024/227930 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*